AbbVie Inc. with ticker code (ABBV) now have 29 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $240.00 and $165.00 suggesting an average Analsyt target price of $204.74. Given that the stocks previous close was at $164.99 and the analysts are correct then there would likely be a percentage uptick in value of 24.1%. Also worth taking note is the 50 day moving average now sits at $191.44 and the 200 moving average now moves to $178.92. The company has a market capitalization of 293.84B. The current share price for the company is: $166.28 USD
The potential market cap would be $364,624,450,047 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 57.74, revenue per share of $31.40 and a 7.72% return on assets.
AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from the AbbVie-owned distribution centers and public warehouses.
